patersc Profile Banner
Christine Jones Profile
Christine Jones

@patersc

Followers
579
Following
39K
Media
116
Statuses
4K

Wife, mum, specialist nurse in Derriford, proud to represent the Peninsula as Meso Uk specialist Nurse. All views are my own.

plymouth
Joined January 2010
Don't wanna be here? Send us removal request.
@LFCKM05
🏆🔴LFCKM05🏆🔴
10 days
There’s no other club for me. No matter whether we lose, draw or win, I’ll forever adore Liverpool Football Club. YNWA🔴❤️ #LFC
23
43
513
@OneScouse
Brian
2 months
Just to be clear. My main aim is to identify who’s a solid red and who’s a soft twat. Identify Listen Block I’ve supported this club all my life.
170
263
3K
@carrotcottagerr
Carrot Cottage Rabbit Rescue
2 months
Our accounts getting throttled because a relentless harasser is tagging us from behind a block and reporting all our posts can you just give Watson a share please 🙏
347
5K
10K
@bmassutis
Bartomeu Massuti
3 months
The conundrum of Malignant Pleural Mesothelioma in patients without asbestos exposure ⁦@OncoAlert#WCLC25
0
9
14
@bmassutis
Bartomeu Massuti
3 months
Phase 2 consolidation Toripalimab in LD Small Cell Lung Cancer HR 0.54 for PFS and reduction CNS progression. Similar to Durvalumab ADRIATIC trial but small size groups at #WCLC25 . @OncoAlert
1
17
58
@DrRiyazShah
Dr Riyaz Shah
3 months
IMig workshop; ASCO thoughts on SACT options in #mesothelioma #WCLC25
0
5
7
@DrRiyazShah
Dr Riyaz Shah
3 months
IMig workshop. Lots of MARS2 critique…. Fair game …. However, I do feel there is an undervaluation of the additional power randomisation adds to one’s understanding RE the utility of a therapeutic intervention #WCLC25
0
4
10
@MatthewEvison1
Matthew Evison
3 months
1/3 The management of stage II/III NSCLC with curative-intent multimodality treatment has undergone unprecedented change in the last decade as immunotherapy and targeted therapies have been into the systemic therapy backbones of treatment. https://t.co/q27jVCIJHh
Tweet card summary image
thorax.bmj.com
Curative-intent multimodality treatment—combining local treatments such as surgery or radiotherapy with systemic therapy—is the cornerstone of care in stage II–III non-small cell lung cancer (NSCLC)....
1
6
12
@DrSanjayPopat
Sanjay Popat
3 months
For those of you wondering why newer antibodies are now called -tugs -barts -migs and -ments not -mabs, this is the official @WHO INN explainer https://t.co/CWemh6ed9x
4
35
124
@mariaguerin1
maria guerin
3 months
This is looking to be a fantastic event Don’t miss out on opportunity to be the owner of some historic memorabilia or experiences @pamstan0104
@SwanTeamLUH
Swan Team
3 months
Anyone who is unable to attend the ball but wishes to place a bid please contact me directly and we will bid on your behalf This event has been arranged by a family dedicated to assisting in SWAN end of life and bereavement care resources #onechancetogetitright
0
4
6
@tnewsomdavis
Tom Newsom-Davis
3 months
@LeXiuning @Alfdoc2 @peters_solange @lungoncdoc @PortalOnconews @oncodaily @MDAndersonNews This week I am working from the inside to learn your 🇺🇸 secrets
2
1
8
@DrRiyazShah
Dr Riyaz Shah
3 months
From a pharmacoeconomics point of view this is a great case study. Osi past the reimbursement threshold in advanced disease as single agent and with chemo. Similarly in adjuvant context. To fail here where the data is a slam dunk is surprising. OS might be key? @BTOGORG
@BTOGORG
BTOG
3 months
BTOG can confirm that NICE has released draft guidance as follows: Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor receptor (EGFR)
5
3
6
@Sinead1989
Sinead McDonagh
3 months
Have you, or a loved one, experienced cancer care in the NHS? We’d love to hear your story. Sign up below to take part in 1 workshop and help shape better care. Please share! @UoEAPEx @CR_UK @PeninsulaCancer @AlzResearchUK @alzassociation @age_uk @NCVNENC @forcecancer
0
8
6
@Swasag1
Swasag
3 months
Great coffee morning in #plymouth today, great to see everyone and all supporting each other. #support #charity #mesothelioma #asbestosawareness
1
5
14
@FordePatrick
Patrick Forde
4 months
Published in today’s print edition of @NEJM the final survival results of neoadjuvant nivo in lung cancer along with a 2 min quick take video & an elegant editorial from Dr. @VirginiaCalvo6 ! #LCSM @gecp_org https://t.co/qbRGfY5iaq
5
53
155
@crispinhiley
Crispin Hiley
4 months
Always great to see patient led decision making for lung cancer therapy. Early stage lung cancer has a very high cure rate with stereotactic radiotherapy (SABR) or surgery. Many patients can be treated with an image guided single radiotherapy treatment. #LCSM
@DrewMoghanaki
Drew Moghanaki
4 months
How high-precision radiation therapy helped a surfer beat lung cancer and get back in the water | UCLA Health
0
3
10
@FordePatrick
Patrick Forde
4 months
Full program for #WCLC25 is now online! Looking forward to Dr. @@Joshua_Reuss oral presentation of neoadjuvant immunotherapy for resectable mesothelioma w liquid biopsy correlates! An investigator-initiated study from start to finish! #LCSM @curemeso
4
19
75
@meso_sheffield
Mesothelioma UK Research Centre - Sheffield
4 months
Evidence based recommendations for health professionals working with people who have peritoneal #mesothelioma.
@Mesouk
Mesothelioma UK
4 months
The @meso_sheffield peritoneal mesothelioma study highlights the need for improved timely diagnosis, enhanced communication between healthcare providers and patients, and referral to specialist mesothelioma multidisciplinary teams. Read more at: https://t.co/pHzvaA0VNC
0
1
2
@LFCVine
Liverpool News
4 months
So true😂
74
2K
16K
@tnewsomdavis
Tom Newsom-Davis
4 months
2L+ Zongertinib for HER2 NSCLC a great step forward 👉 Clear clinical activity 👉 Much better TRAEs than 1G TKIs, and 🔽 diarrhoea than BAY88 rival 👉 1L trials ongoing: best place for this agent IMO 👉 Optimal sequencing with ADC unknown 👉 🇬🇧 needs access to HER2 drugs #LCSM
@SuyogCancer
Dr Amol Akhade
4 months
FDA Accelerated Approval Zongertinib (Hernexeos) for adults with HER2 (ERBB2) TKD-mutant unresectable/metastatic non-sq #NSCLC after prior therapy 🫁 ✅ ORR: 75% (no prior HER2-ADC) | 44% (post HER2-ADC) 💊 Daily oral TKI | Companion Dx: Oncomine Dx Target Test ⚠️ Watch for
1
4
30